Two Sigma Investments
PRVL

Two Sigma Investments’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Two Sigma Investments’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,082
Closed -$371K – 4410
2020
Q4 		$371K Sell
16,082
-28,331
-64% -$359K ﹤0.01% 2714
2020
Q3 		$452K Buy
44,413
+21,149
+91% +$284K ﹤0.01% 2322
2020
Q2 		$347K Buy
23,264
+2,953
+15% +$45.5K ﹤0.01% 2281
2020
Q1 		$248K Buy
+20,311
New +$323K ﹤0.01% 2481

Two Sigma Investments's PRVL Position: Q1 2021 in Review

Two Sigma Investments sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 16,082 shares — an estimated $371K sold.

Two Sigma Investments first reported a position in PRVL in Q1 2020 and held it in 4 quarters. The position peaked at $452K in Q3 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Two Sigma Investments reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Two Sigma Investments sold 16,082 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $371K.
  • Two Sigma Investments first reported a position in Prevail Therapeutics Inc. Common Stock in Q1 2020 and held it in 4 quarters.
  • Two Sigma Investments's Prevail Therapeutics Inc. Common Stock position peaked at $452K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Two Sigma Investments's 13F filing for Q1 2021, filed 17 May 2021.